AbsEn.i
Curation
Istex
Racine
Curation
Checkpoint
Istex
Racine
Istex
Exploration
Accueil
Racine
Racine

Serveur d'exploration Tocilizumab - Curation (Istex)

Index « AbsEn.i » - entrée « development »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
developing < development < developments  Facettes :

List of bibliographic references

Number of relevant bibliographic references: 106.
[0-20] [0 - 20][0 - 50][20-40]
Ident.Authors (with country if any)Title
000000 (2009) Susan P. Bruce [États-Unis]Recent Developments in the Treatment of Rheumatoid Arthritis
000024 (2012) A. Finet [France] ; M. Amini-Adle [France] ; B. Balme [France] ; F. Colson [France] ; L. Thomas [France]Nodular progression of lentigo malignant melanoma during a treatment with tocilizumab: cause or coincidence?
000039 (2011) Toshio Tanaka [Japon] ; Keisuke Hagihara [Japon] ; Yoshihito Shima [Japon] ; Masashi Narazaki [Japon] ; Atsushi Ogata [Japon] ; Atsushi Kumanogoh [Japon]Tocilizumab, a humanized anti‐interleukin‐6 receptor antibody, for the treatment of autoimmune disorders
000041 (2014) P. Jayasekera [Royaume-Uni] ; R. Parslew [Royaume-Uni] ; A. Al-Sharqi [Royaume-Uni]A case of tumour necrosis factor‐α inhibitor‐ and rituximab‐induced plantar pustular psoriasis that completely resolved with tocilizumab
000128 (2015) Shunichi Fujita [Japon] ; Nami Kosaka [Japon] ; Takafumi Mito [Japon] ; Hiroaki Hayashi [Japon] ; Yoshitaka Morita [Japon]Development of aseptic subcutaneous abscess after tocilizumab therapy in a patient with SAPHO syndrome complicated by amyloid A amyloidosis
000140 (2012) M. Rauner [Allemagne] ; L. C. Hofbauer [Allemagne] ; M. Aringer [Allemagne]Lokale und systemische Knocheneffekte bei rheumatoider Arthritis
000145 (2012) I. Demin [Suisse] ; B. Hamrén [Suisse] ; O. Luttringer [Suisse] ; G. Pillai [Suisse] ; T. Jung [Suisse]Longitudinal Model‐Based Meta‐Analysis in Rheumatoid Arthritis: An Application Toward Model‐Based Drug Development
000148 (2013) L. Naumann [Allemagne] ; E. Feist [Allemagne] ; G.-R. Burmester [Allemagne]Antizytokintherapie
000173 (2013) Nam Trung Nguyen [Japon, Viêt Nam] ; Taisuke Nakahama [Japon] ; Tadamitsu Kishimoto [Japon]Aryl hydrocarbon receptor and experimental autoimmune arthritis
000181 (2015) Yi Zhang [États-Unis] ; Xiaohui Wei [États-Unis] ; Gaurav Bajaj [États-Unis] ; Jeffrey S. Barrett [États-Unis] ; Bernd Meibohm [États-Unis] ; Amita Joshi [États-Unis] ; Manish Gupta [États-Unis]Challenges and considerations for development of therapeutic proteins in pediatric patients
000204 (2010) C. J. Edwards [Royaume-Uni] ; E. Williams [Royaume-Uni]The role of interleukin-6 in rheumatoid arthritis-associated osteoporosis
000216 (2012) K. Albrecht [Allemagne] ; K. Krüger [Allemagne] ; U. Müller-Ladner [Allemagne] ; J. Wollenhaupt [Allemagne]Systematische Literaturrecherche für die S1-Leitlinie zur sequenziellen medikamentösen Therapie der rheumatoiden Arthritis
000227 (2006) Marcus D. Köller [Autriche]Targeted therapy in rheumatoid arthritis
000233 (2010) Hiroshi Kato [États-Unis] ; David A. Fox [États-Unis]Are Th17 Cells an Appropriate New Target in the Treatment of Rheumatoid Arthritis?
000258 (2010) Scott M. Steward-Tharp [États-Unis, Royaume-Uni] ; Yun-Jeong Song [États-Unis] ; Richard M. Siegel [États-Unis] ; John J. O'Shea [États-Unis]New insights into T cell biology and T cell‐directed therapy for autoimmunity, inflammation, and immunosuppression
000282 (2010) Gert Hein [Allemagne] ; Thorsten Eidner [Allemagne] ; Peter Oelzner [Allemagne] ; Michael Rose [Allemagne] ; Alexander Wilke [Allemagne] ; Gunter Wolf [Allemagne] ; Sybille Franke [Allemagne]Influence of Rituximab on markers of bone remodeling in patients with rheumatoid arthritis: a prospective open-label pilot study
000296 (2012) Adel Alawadhi [Koweït] ; Khaldoon Alawneh [Jordanie] ; Zeyad Ahmed Alzahrani [Arabie saoudite]The effect of neutralizing antibodies on the sustainable efficacy of biologic therapies: what’s in it for African and Middle Eastern rheumatologists
000299 (2011) Nada Kherbeck [France] ; Mathieu C. Tamby [France] ; Guillaume Bussone [France] ; Hanadi Dib [France] ; Frederic Perros [France] ; Marc Humbert [France] ; Luc Mouthon [France]The Role of Inflammation and Autoimmunity in the Pathophysiology of Pulmonary Arterial Hypertension
000300 (2012) Joerg-Patrick Stübgen [États-Unis]Targeted immunotherapy trials for idiopathic inflammatory myopathies
000304 (2013) Tomokazu Nagao ; Reina Kusunoki ; Chiaki Iwamura ; Shigeto Kobayashi ; Wako Yumura ; Yosuke Kameoka [Japon] ; Toshinori Nakayama ; Kazuo Suzuki [Japon]Correlation of interleukin‐6 and monocyte chemotactic protein‐1 concentrations with crescent formation and myeloperoxidase‐specific anti‐neutrophil cytoplasmic antibody titer in SCG/Kj mice by treatment with anti‐interleukin‐6 receptor antibody or mizoribine
000337 (2011) Sylvie Fabre [France]Approches pharmacologiques en immuno-rhumatologie

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/Istex/Curation

HfdIndexSelect -h $EXPLOR_AREA/Data/Istex/Curation/AbsEn.i -k "development" 

HfdIndexSelect -h $EXPLOR_AREA/Data/Istex/Curation/AbsEn.i  \
                -Sk "development" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Istex/Curation/biblio.hfd

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    TocilizumabV1
   |flux=    Istex
   |étape=   Curation
   |type=    indexItem
   |index=    AbsEn.i
   |clé=    development
}}
Wicri

This area was generated with Dilib version V0.6.34.
Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021